Baik Lin Seong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5889617/publications.pdf

Version: 2024-02-01

159358 197535 3,064 112 30 49 citations g-index h-index papers 114 114 114 4427 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes. Virology, 2022, 566, 143-152.	1.1	2
2	Chaperna: linking the ancient RNA and protein worlds. RNA Biology, 2021, 18, 16-23.	1.5	9
3	Filamentous anti-influenza agents wrapping around viruses. Journal of Colloid and Interface Science, 2021, 583, 267-278.	5.0	10
4	A social distancing measure governing the whole proteome. Current Opinion in Structural Biology, 2021, 66, 104-111.	2.6	3
5	RNA-assisted self-assembly of monomeric antigens into virus-like particles as a recombinant vaccine platform. Biomaterials, 2021, 269, 120650.	5.7	13
6	Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses. Vaccines, 2021, 9, 353.	2.1	11
7	A Conceptual Framework for Integrating Cellular Protein Folding, Misfolding and Aggregation. Life, 2021, 11, 605.	1.1	4
8	RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102438.	1.7	4
9	Epigallocatechin-3-Gallate as a Novel Vaccine Adjuvant. Frontiers in Immunology, 2021, 12, 769088.	2.2	12
10	A Host-Restricted Self-Attenuated Influenza Virus Provides Broad Pan-Influenza A Protection in a Mouse Model. Frontiers in Immunology, 2021, 12, 779223.	2.2	2
11	Solubility, Stability, and Avidity of Recombinant Antibody Fragments Expressed in Microorganisms. Frontiers in Microbiology, 2020, 11, 1927.	1.5	43
12	Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process. Archives of Pharmacal Research, 2020, 43, 714-723.	2.7	0
13	Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection. Expert Opinion on Drug Discovery, 2020, 15, 1441-1455.	2.5	10
14	Bead based facile assay for sensitive quantification of native state green fluorescent protein. RSC Advances, 2020, 10, 13095-13099.	1.7	3
15	Causality Assessment Guidelines for Adverse Events Following Immunization with a Focus on Guillain–BarrĀ© Syndrome. Vaccines, 2020, 8, 101.	2.1	5
16	Builtâ€in RNAâ€mediated chaperone (chaperna) for antigen folding tailored to immunized hosts. Biotechnology and Bioengineering, 2020, 117, 1990-2007.	1.7	5
17	RNA-binding as chaperones of DNA binding proteins from starved cells. Biochemical and Biophysical Research Communications, 2020, 524, 484-489.	1.0	5
18	Cost-effectiveness analysis of the implementation of a National Immunization Program for rotavirus vaccination in a country with a low rotavirus gastroenteritis-related mortality: A South Korean study. Vaccine, 2019, 37, 4987-4995.	1.7	12

#	Article	IF	CITATIONS
19	Stabilization of Intrinsically Disordered DKK2 Protein by Fusion to RNA-Binding Domain. International Journal of Molecular Sciences, 2019, 20, 2847.	1.8	5
20	The Quest for a Truly Universal Influenza Vaccine. Frontiers in Cellular and Infection Microbiology, 2019, 9, 344.	1.8	51
21	The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants. Antiviral Research, 2019, 168, 100-108.	1.9	2
22	Coâ€degradation of interferon signaling factor DDX3 by PB1â€F2 as a basis for high virulence of 1918 pandemic influenza. EMBO Journal, 2019, 38, .	3.5	26
23	Quality Screening of Incorrectly Folded Soluble Aggregates from Functional Recombinant Proteins. International Journal of Molecular Sciences, 2019, 20, 907.	1.8	7
24	Universal monoclonal antibody-based influenza hemagglutinin quantitative enzyme-linked immunosorbent assay. Vaccine, 2019, 37, 1457-1466.	1.7	20
25	Conversion of a soluble protein into a potent chaperone in vivo. Scientific Reports, 2019, 9, 2735.	1.6	6
26	Hemagglutinin Quantitative ELISA-based Potency Assay for Trivalent Seasonal Influenza Vaccine Using Group-Specific Universal Monoclonal Antibodies. Scientific Reports, 2019, 9, 19675.	1.6	7
27	Novel antiviral drug discovery strategies to tackle drug-resistant mutants of influenza virus strains. Expert Opinion on Drug Discovery, 2019, 14, 153-168.	2.5	31
28	Virucidal nano-perforator of viral membrane trapping viral RNAs in the endosome. Nature Communications, 2019, 10, 185.	5.8	35
29	Characterization of the molecular events of covalently closed circular DNA synthesis in de novo Hepatitis B virus infection of human hepatoma cells. Antiviral Research, 2019, 163, 11-18.	1.9	25
30	RNAâ€dependent chaperone (chaperna) as an engineered proâ€region for the folding of recombinant microbial transglutaminase. Biotechnology and Bioengineering, 2019, 116, 490-502.	1.7	8
31	Purification of antibody fragments for the reduction of charge variants using cation exchange chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1080, 20-26.	1.2	14
32	Harnessing an RNAâ€mediated chaperone for the assembly of influenza hemagglutinin in an immunologically relevant conformation. FASEB Journal, 2018, 32, 2658-2675.	0.2	20
33	Recombinant adenylate kinase 3 from liver fluke <i>Clonorchis sinensis</i> for histochemical analysis and serodiagnosis of clonorchiasis. Parasitology, 2018, 145, 1531-1539.	0.7	7
34	Suppression of interferon-mediated anti-HBV response by single CpG methylation in the 5′-UTR of <i>TRIM22</i> . Gut, 2018, 67, 166-178.	6.1	56
35	Nucleic Acid-Dependent Structural Transition of the Intrinsically Disordered N-Terminal Appended Domain of Human Lysyl-tRNA Synthetase. International Journal of Molecular Sciences, 2018, 19, 3016.	1.8	11
36	Development of a diagnostic system for detection of specific antibodies and antigens against Middle East respiratory syndrome coronavirus. Microbiology and Immunology, 2018, 62, 574-584.	0.7	9

#	Article	lF	CITATIONS
37	Eliciting unnatural immune responses by activating cryptic epitopes in viral antigens. FASEB Journal, 2018, 32, 4658-4669.	0.2	3
38	Pan-Influenza A Protection by Prime–Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. Frontiers in Immunology, 2018, 9, 116.	2.2	11
39	Chaperna-Mediated Assembly of Ferritin-Based Middle East Respiratory Syndrome-Coronavirus Nanoparticles. Frontiers in Immunology, 2018, 9, 1093.	2.2	82
40	Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. Frontiers in Microbiology, 2018, 9, 83.	1.5	40
41	Glycosylation of Hemagglutinin and Neuraminidase of Influenza A Virus as Signature for Ecological Spillover and Adaptation among Influenza Reservoirs. Viruses, 2018, 10, 183.	1.5	35
42	Evaluation of green tea extract as a safe personal hygiene against viral infections. Journal of Biological Engineering, 2018, 12, 1.	2.0	59
43	Cell-cultured, live attenuated, X-31ca-based H5N1 pre-pandemic influenza vaccine. Virology, 2017, 504, 73-78.	1.1	2
44	Exploiting virus-like particles as innovative vaccines against emerging viral infections. Journal of Microbiology, 2017, 55, 220-230.	1.3	59
45	The folding competence of HIV-1 Tat mediated by interaction with TAR RNA. RNA Biology, 2017, 14, 926-937.	1.5	27
46	Highly chromophoric Cy5-methionine for N-terminal fluorescent tagging of proteins in eukaryotic translation systems. Scientific Reports, 2017, 7, 11642.	1.6	7
47	Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. Expert Opinion on Drug Discovery, 2017, 12, 1139-1152.	2.5	20
48	Green Tea Catechin-Inactivated Viral Vaccine Platform. Frontiers in Microbiology, 2017, 8, 2469.	1.5	9
49	Toward a universal influenza vaccine: a retrospective. Future Virology, 2016, 11, 313-316.	0.9	1
50	Genetic analysis of attenuation markers of cold-adapted X-31 influenza live vaccine donor strain. Vaccine, 2016, 34, 1343-1349.	1.7	13
51	Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin. Virology, 2016, 491, 1-9.	1.1	5
52	Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice. PLoS ONE, 2016, 11, e0152485.	1.1	9
53	M1 RNA is important for the in-cell solubility of its cognate C5 protein: Implications for RNA-mediated protein folding. RNA Biology, 2015, 12, 1198-1208.	1.5	26
54	Inactivated Eyedrop Influenza Vaccine Adjuvanted with Poly(I:C) Is Safe and Effective for Inducing Protective Systemic and Mucosal Immunity. PLoS ONE, 2015, 10, e0137608.	1.1	24

#	Article	IF	Citations
55	Options and Obstacles for Designing a Universal Influenza Vaccine. Viruses, 2014, 6, 3159-3180.	1.5	40
56	Protective efficacy in mice of monovalent and trivalent live attenuated influenza vaccines in the background of cold-adapted A/X-31 and B/Lee/40 donor strains. Vaccine, 2014, 32, 535-543.	1.7	17
57	High-yield soluble expression of recombinant influenza virus antigens from Escherichia coli and their potential uses in diagnosis. Journal of Virological Methods, 2014, 196, 56-64.	1.0	11
58	Intranasal Adenovirus-Vectored Vaccine for Induction of Long-Lasting Humoral Immunity-Mediated Broad Protection against Influenza in Mice. Journal of Virology, 2014, 88, 9693-9703.	1.5	31
59	The effect of intracellular protein delivery on the anti-tumor activity ofÂrecombinant human endostatin. Biomaterials, 2013, 34, 6261-6271.	5.7	15
60	Cold-adapted X-31 live attenuated 2009 pandemic H1N1 influenza vaccine elicits protective immune responses in mice and ferrets. Vaccine, 2013, 31, 1320-1327.	1.7	13
61	Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines. Vaccine, 2013, 31, 3339-3346.	1.7	12
62	Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Expert Opinion on Drug Discovery, 2013, 8, 411-426.	2.5	14
63	Hepatitis B virus inhibits liver regeneration via epigenetic regulation of urokinase-type plasminogen activator. Hepatology, 2013, 58, 762-776.	3.6	39
64	Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines. Yonsei Medical Journal, 2013, 54, 271.	0.9	30
65	Toward a universal influenza vaccine: from the perspective of protective efficacy. Clinical and Experimental Vaccine Research, 2013, 2, 71.	1.1	7
66	Host Defense Mechanism-Based Rational Design of Live Vaccine. PLoS ONE, 2013, 8, e75043.	1.1	14
67	Protein Folding In Vivo Revisited. Current Protein and Peptide Science, 2013, 14, 721-733.	0.7	17
68	Macromolecule-Assisted de novo Protein Folding. International Journal of Molecular Sciences, 2012, 13, 10368-10386.	1.8	9
69	Cold-Adapted Pandemic 2009 H1N1 Influenza Virus Live Vaccine Elicits Cross-Reactive Immune Responses against Seasonal and H5 Influenza A Viruses. Journal of Virology, 2012, 86, 5953-5958.	1.5	42
70	RPS3a Over-Expressed in HBV-Associated Hepatocellular Carcinoma Enhances the HBx-Induced NF-κB Signaling via Its Novel Chaperoning Function. PLoS ONE, 2011, 6, e22258.	1.1	42
71	Chaperoning Roles of Macromolecules Interacting with Proteins in Vivo. International Journal of Molecular Sciences, 2011, 12, 1979-1990.	1.8	14
72	Type I Interferon Signaling Regulates Ly6Chi Monocytes and Neutrophils during Acute Viral Pneumonia in Mice. PLoS Pathogens, 2011, 7, e1001304.	2.1	186

#	Article	IF	Citations
73	Sublingual Immunization with M2-Based Vaccine Induces Broad Protective Immunity against Influenza. PLoS ONE, 2011, 6, e27953.	1.1	66
74	Genotyping and screening of reassortant live-attenuated influenza B vaccine strain. Journal of Virological Methods, 2010, 165, 133-138.	1.0	9
75	Prophylactic and Therapeutic Efficacy of Avian Antibodies Against Influenza Virus H5N1 and H1N1 in Mice. PLoS ONE, 2010, 5, e10152.	1.1	68
76	MyD88 Signaling Is Indispensable for Primary Influenza A Virus Infection but Dispensable for Secondary Infection. Journal of Virology, 2010, 84, 12713-12722.	1.5	82
77	Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Experimental and Molecular Medicine, 2010, 42, 116.	3.2	21
78	5S rRNA-assisted DnaK refolding. Biochemical and Biophysical Research Communications, 2010, 391, 1177-1181.	1.0	16
79	Production and characterization of active hepatitis C virus RNA-dependent RNA polymerase. Protein Expression and Purification, 2010, 71, 147-152.	0.6	2
80	Inactivation of H1N1 viruses exposed to acidic ozone water. Applied Physics Letters, 2009, 95, 173704.	1.5	10
81	RNA-mediated chaperone type for de novo protein folding. RNA Biology, 2009, 6, 21-24.	1.5	57
82	Identification of novel inhibitors of HCV RNA-dependent RNA polymerase by pharmacophore-based virtual screening and in vitro evaluation. Bioorganic and Medicinal Chemistry, 2009, 17, 2975-2982.	1.4	31
83	Identification and Use of Zinc Finger Transcription Factors That Increase Production of Recombinant Proteins in Yeast and Mammalian Cells. Biotechnology Progress, 2008, 21, 664-670.	1.3	26
84	Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea. Veterinary Microbiology, 2008, 130, 268-276.	0.8	21
85	Assessment of substrate-stabilizing factors for DnaK on the folding of aggregation-prone proteins. Biochemical and Biophysical Research Communications, 2008, 373, 74-79.	1.0	13
86	Protein Solubility and Folding Enhancement by Interaction with RNA. PLoS ONE, 2008, 3, e2677.	1.1	63
87	Immediate and broad-spectrum protection against heterologous and heterotypic lethal challenge in mice by live influenza vaccine. Vaccine, 2007, 25, 8067-8076.	1.7	28
88	Tea catechins as a potential alternative anti-infectious agent. Expert Review of Anti-Infective Therapy, 2007, 5, 497-506.	2.0	62
89	Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Research, 2007, 76, 178-185.	1.9	57
90	N-terminal domains of native multidomain proteins have the potential to assist de novo folding of their downstream domains in vivo by acting as solubility enhancers. Protein Science, 2007, 16, 635-643.	3.1	38

#	Article	IF	Citations
91	Cell-Permeable and Biocompatible Polymeric Nanoparticles for Apoptosis Imaging. Journal of the American Chemical Society, 2006, 128, 3490-3491.	6.6	237
92	Design and Biological Evaluation of Novel Tubulin Inhibitors as Antimitotic Agents Using a Pharmacophore Binding Model with Tubulin. Journal of Medicinal Chemistry, 2006, 49, 5664-5670.	2.9	76
93	Characterization of live influenza vaccine donor strain derived from cold-adaptation of X-31 virus. Vaccine, 2006, 24, 1966-1974.	1.7	30
94	A multiplex RT-PCR method for screening of reassortant live influenza vaccine virus strains. Journal of Virological Methods, 2006, 134, 154-163.	1.0	12
95	N-Glycosylation of secretion enhancer peptide as influencing factor for the secretion of target proteins from Saccharomyces cerevisiae. Biochemical and Biophysical Research Communications, 2005, 337, 557-562.	1.0	6
96	Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO Journal, 2003, 22, 2104-2116.	3.5	120
97	Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. Journal of Medical Virology, 2003, 71, 367-375.	2.5	35
98	Engineered Recombinant Enteropeptidase Catalytic Subunit: Effect of N-Terminal Modification. Archives of Biochemistry and Biophysics, 2002, 400, 1-6.	1.4	14
99	Investigation of Antigen Delivery Route in Vivo and Immune-Boosting Effects Mediated by pH-Sensitive Liposomes Encapsulated with Kb-Restricted CTL Epitope. Biochemical and Biophysical Research Communications, 2002, 292, 682-688.	1.0	14
100	Extracellular zinc stimulates ERK-dependent activation of p21Cip/WAF1 and inhibits proliferation of colorectal cancer cells. British Journal of Pharmacology, 2002, 137, 597-607.	2.7	55
101	Characterization of HLA-A2.1-restricted epitopes, conserved in both Hantaan and Sin Nombre viruses, in Hantaan virus-infected patients. Journal of General Virology, 2002, 83, 1131-1136.	1.3	20
102	Peptide amidation: Production of peptide hormonesin vivo andin vitro. Biotechnology and Bioprocess Engineering, 2001, 6, 244-251.	1.4	51
103	Recombinant enterokinase light chain with affinity tag: Expression from Saccharomyces cerevisiae and its utilities in fusion protein technology. Biotechnology and Bioengineering, 2001, 75, 718-724.	1.7	63
104	Structure of influenza virus panhandle RNA studied by NMR spectroscopy and molecular modeling. Nucleic Acids Research, 1999, 27, 1392-1397.	6.5	26
105	Novel Secretion System of Recombinant Saccharomyces cerevisiae Using an N-terminus Residue of Human IL- $\hat{\Pi}^2$ as Secretion Enhancer. Biotechnology Progress, 1999, 15, 884-890.	1.3	16
106	Current status for influenza control. Biotechnology and Bioprocess Engineering, 1999, 4, 157-164.	1.4	1
107	Enhanced secretion of human granulocyte colony-stimulating factor directed by a novel hybrid fusion peptide from recombinantSaccharomyces cerevisiae at high cell concentration., 1998, 57, 600-609.		27
108	Comparison of Two Reconstituted Systems for In Vitro Transcription and Replication of Influenza Virus1. Journal of Biochemistry, 1992, 111, 496-499.	0.9	31

#	Article	IF	CITATION
109	Microbial transformation of rifamycin B: A new synthetic approach to rifamycin derivatives Journal of Antibiotics, 1983, 36, 1402-1404.	1.0	23
110	A FACILE PREPARATION OF RIFAMYCIN DERIVATIVES BY USE OF MANGANESE DIOXIDE. Chemistry Letters, 1982, 11, 627-628.	0.7	19
111	The production of 6-aminopenicillanic acid by a multistage tubular reactor packed with immobilized penicillin amidase. Biotechnology and Bioengineering, 1982, 24, 1623-1637.	1.7	24
112	Effect of mass transfer in a recirculation batch reactor system for immobilized penicillin amidase. Biotechnology and Bioengineering, 1982, 24, 2215-2226.	1.7	15